메뉴 건너뛰기




Volumn 13, Issue 4, 2015, Pages 424-434

Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms

(26)  Stein, Brady L a   Gotlib, Jason b   Arcasoy, Murat c   Nguyen, Marie Huong d   Shah, Neil e   Moliterno, Alison f   Jamieson, Catriona g   Pollyea, Daniel A h   Scott, Bart i   Wadleigh, Martha j   Levine, Ross k   Komrokji, Rami l   Klisovic, Rebecca m   Gundabolu, Krishna n   Kropf, Patricia o   Wetzler, Meir p   Oh, Stephen T q   Ribeiro, Raul r   Paschal, Rita s   Mohan, Sanjay t   more..


Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HYDROXYUREA; JANUS KINASE; JANUS KINASE INHIBITOR; ANTINEOPLASTIC AGENT; CALRETICULIN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; MPL PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; THROMBOPOIETIN RECEPTOR;

EID: 84928039932     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0058     Document Type: Review
Times cited : (25)

References (110)
  • 1
    • 38349060667 scopus 로고    scopus 로고
    • The history of myeloproliferative disorders: Before and after Dameshek
    • Tefferi A. The history of myeloproliferative disorders: before and after Dameshek. Leukemia 2008;22:3-13.
    • (2008) Leukemia , vol.22 , pp. 3-13
    • Tefferi, A.1
  • 2
    • 0001639195 scopus 로고
    • Some speculations on the myeloproliferative syndromes
    • Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6:372-375.
    • (1951) Blood , vol.6 , pp. 372-375
    • Dameshek, W.1
  • 3
    • 17844383458 scopus 로고    scopus 로고
    • A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
    • James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148.
    • (2005) Nature , vol.434 , pp. 1144-1148
    • James, C.1    Ugo, V.2    Le Couedic, J.P.3
  • 4
    • 84894415792 scopus 로고    scopus 로고
    • Epidemiology of myeloproliferative neoplasms in the United States
    • Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymph 2014;55:595-600.
    • (2014) Leuk Lymph , vol.55 , pp. 595-600
    • Mehta, J.1    Wang, H.2    Iqbal, S.U.3    Mesa, R.4
  • 5
    • 84897929701 scopus 로고    scopus 로고
    • Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN)
    • Price GL, Davis KL, Karve S, et al. Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One 2014;9:e90299.
    • (2014) PLoS One , vol.9 , pp. e90299
    • Price, G.L.1    Davis, K.L.2    Karve, S.3
  • 6
    • 84902595006 scopus 로고    scopus 로고
    • Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: Retrospective assessment in 1470 patients
    • Geyer HL, Emanuel RM, Dueck AC, et al. Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood 2014;12;123:3803-3810.
    • (2014) Blood , vol.12 , Issue.123 , pp. 3803-3810
    • Geyer, H.L.1    Emanuel, R.M.2    Dueck, A.C.3
  • 7
    • 33846266634 scopus 로고    scopus 로고
    • The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international Internet-based survey of 1179 MPD patients
    • Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007;109:68-76.
    • (2007) Cancer , vol.109 , pp. 68-76
    • Mesa, R.A.1    Niblack, J.2    Wadleigh, M.3
  • 8
    • 79960437973 scopus 로고    scopus 로고
    • The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients
    • Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 2011;118:401-408.
    • (2011) Blood , vol.118 , pp. 401-408
    • Scherber, R.1    Dueck, A.C.2    Johansson, P.3
  • 9
    • 84869381382 scopus 로고    scopus 로고
    • Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs
    • Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012;30:4098-4103.
    • (2012) J Clin Oncol , vol.30 , pp. 4098-4103
    • Emanuel, R.M.1    Dueck, A.C.2    Geyer, H.L.3
  • 10
    • 63849328927 scopus 로고    scopus 로고
    • New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
    • Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-2901.
    • (2009) Blood , vol.113 , pp. 2895-2901
    • Cervantes, F.1    Dupriez, B.2    Pereira, A.3
  • 11
    • 77950352432 scopus 로고    scopus 로고
    • A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
    • Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703-1708.
    • (2010) Blood , vol.115 , pp. 1703-1708
    • Passamonti, F.1    Cervantes, F.2    Vannucchi, A.M.3
  • 12
    • 79952087335 scopus 로고    scopus 로고
    • DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status
    • Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392-397.
    • (2011) J Clin Oncol , vol.29 , pp. 392-397
    • Gangat, N.1    Caramazza, D.2    Vaidya, R.3
  • 13
    • 33746437130 scopus 로고    scopus 로고
    • MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia
    • Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
    • (2006) PLoS Med , vol.3 , pp. e270
    • Pikman, Y.1    Lee, B.H.2    Mercher, T.3
  • 14
    • 33750534561 scopus 로고    scopus 로고
    • MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients
    • Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108:3472-3476.
    • (2006) Blood , vol.108 , pp. 3472-3476
    • Pardanani, A.D.1    Levine, R.L.2    Lasho, T.3
  • 15
    • 33846660947 scopus 로고    scopus 로고
    • JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
    • Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-468.
    • (2007) N Engl J Med , vol.356 , pp. 459-468
    • Scott, L.M.1    Tong, W.2    Levine, R.L.3
  • 16
    • 84883649589 scopus 로고    scopus 로고
    • Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis
    • Spolverini A, Pieri L, Guglielmelli P, et al. Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. Haematologica 2013;98:e101-102.
    • (2013) Haematologica , vol.98 , pp. e101-e102
    • Spolverini, A.1    Pieri, L.2    Guglielmelli, P.3
  • 18
    • 84890372480 scopus 로고    scopus 로고
    • Somatic mutations of calreticulin in myeloproliferative neoplasms
    • Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379-2390.
    • (2013) N Engl J Med , vol.369 , pp. 2379-2390
    • Klampfl, T.1    Gisslinger, H.2    Harutyunyan, A.S.3
  • 19
    • 84890328032 scopus 로고    scopus 로고
    • Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2
    • Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-2405.
    • (2013) N Engl J Med , vol.369 , pp. 2391-2405
    • Nangalia, J.1    Massie, C.E.2    Baxter, E.J.3
  • 20
    • 84919467186 scopus 로고    scopus 로고
    • Presence of calreticulin mutations in JAK2-negative polycythemia vera
    • Broseus J, Park JH, Carillo S, et al. Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood 2014:124:3964-3966.
    • (2014) Blood , vol.124 , pp. 3964-3966
    • Broseus, J.1    Park, J.H.2    Carillo, S.3
  • 21
    • 84905990634 scopus 로고    scopus 로고
    • Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
    • Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 2014;124:1062-1069.
    • (2014) Blood , vol.124 , pp. 1062-1069
    • Rumi, E.1    Pietra, D.2    Pascutto, C.3
  • 22
    • 84908147447 scopus 로고    scopus 로고
    • Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis
    • quiz 2615
    • Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis. Blood 2014;124:2507-2513; quiz 2615.
    • (2014) Blood , vol.124 , pp. 2507-2513
    • Tefferi, A.1    Guglielmelli, P.2    Larson, D.R.3
  • 23
    • 84908065771 scopus 로고    scopus 로고
    • The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants
    • Tefferi A, Lasho TL, Tischer A, et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood 2014;124:2465-2466.
    • (2014) Blood , vol.124 , pp. 2465-2466
    • Tefferi, A.1    Lasho, T.L.2    Tischer, A.3
  • 24
    • 84883742034 scopus 로고    scopus 로고
    • Mutations and prognosis in primary myelofibrosis
    • Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27:1861-1869.
    • (2013) Leukemia , vol.27 , pp. 1861-1869
    • Vannucchi, A.M.1    Lasho, T.L.2    Guglielmelli, P.3
  • 25
    • 34548042964 scopus 로고    scopus 로고
    • Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel
    • Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-1097.
    • (2007) Blood , vol.110 , pp. 1092-1097
    • Tefferi, A.1    Thiele, J.2    Orazi, A.3
  • 26
    • 46749132374 scopus 로고    scopus 로고
    • The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: A report on 241 cases
    • Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008;111:4922-4929.
    • (2008) Blood , vol.111 , pp. 4922-4929
    • Kiladjian, J.J.1    Cervantes, F.2    Leebeek, F.W.3
  • 27
    • 47649121826 scopus 로고    scopus 로고
    • The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: An alternative proposal
    • Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 2008;112:231-239.
    • (2008) Blood , vol.112 , pp. 231-239
    • Spivak, J.L.1    Silver, R.T.2
  • 28
    • 80051803115 scopus 로고    scopus 로고
    • Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study
    • Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011;29:3179-3184.
    • (2011) J Clin Oncol , vol.29 , pp. 3179-3184
    • Barbui, T.1    Thiele, J.2    Passamonti, F.3
  • 29
    • 74049112732 scopus 로고    scopus 로고
    • Prodromal myeloproliferative neoplasms: The 2008 WHO classification
    • Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol 2010;85:62-69.
    • (2010) Am J Hematol , vol.85 , pp. 62-69
    • Kvasnicka, H.M.1    Thiele, J.2
  • 30
    • 38049188368 scopus 로고    scopus 로고
    • Bone marrow pathology in essential thrombocythemia: Interobserver reliability and utility for identifying disease subtypes
    • Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 2008;111:60-70.
    • (2008) Blood , vol.111 , pp. 60-70
    • Wilkins, B.S.1    Erber, W.N.2    Bareford, D.3
  • 31
    • 84892882972 scopus 로고    scopus 로고
    • Masked polycythemia vera (mPV): Results of an international study
    • Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol 2014;89:52-54.
    • (2014) Am J Hematol , vol.89 , pp. 52-54
    • Barbui, T.1    Thiele, J.2    Gisslinger, H.3
  • 32
    • 84902077783 scopus 로고    scopus 로고
    • Rethinking the diagnostic criteria of polycythemia vera
    • Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rethinking the diagnostic criteria of polycythemia vera. Leukemia 2013;28:1191-1195.
    • (2013) Leukemia , vol.28 , pp. 1191-1195
    • Barbui, T.1    Thiele, J.2    Vannucchi, A.M.3    Tefferi, A.4
  • 33
    • 84893964717 scopus 로고    scopus 로고
    • Masked polycythemia vera diagnosed according to WHO and BCSH classification
    • Barbui T, Thiele J, Carobbio A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol 2014;89:199-202.
    • (2014) Am J Hematol , vol.89 , pp. 199-202
    • Barbui, T.1    Thiele, J.2    Carobbio, A.3
  • 34
    • 84887373344 scopus 로고    scopus 로고
    • Evaluation of WHO criteria for diagnosis of polycythemia vera: A prospective analysis
    • Silver RT, Chow W, Orazi A, et al. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 2013;122:1881-1886.
    • (2013) Blood , vol.122 , pp. 1881-1886
    • Silver, R.T.1    Chow, W.2    Orazi, A.3
  • 35
    • 39149090683 scopus 로고    scopus 로고
    • Classification of myeloproliferative disorders in the JAK2 era: Is there a role for red cell mass?
    • Cassinat B, Laguillier C, Gardin C, et al. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia 2008;22:452-453.
    • (2008) Leukemia , vol.22 , pp. 452-453
    • Cassinat, B.1    Laguillier, C.2    Gardin, C.3
  • 36
    • 84868556615 scopus 로고    scopus 로고
    • Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia
    • Alvarez-Larran A, Ancochea A, Angona A, et al. Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica 2012;97:1704-1707.
    • (2012) Haematologica , vol.97 , pp. 1704-1707
    • Alvarez-Larran, A.1    Ancochea, A.2    Angona, A.3
  • 37
    • 84904067758 scopus 로고    scopus 로고
    • An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms
    • Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014;28:1407-1413.
    • (2014) Leukemia , vol.28 , pp. 1407-1413
    • Tefferi, A.1    Thiele, J.2    Vannucchi, A.M.3    Barbui, T.4
  • 38
    • 84871501896 scopus 로고    scopus 로고
    • Development and validation of an International Prognostic Score of thrombosis in World Health Organization: Essential thrombocythemia (IPSET-thrombosis)
    • quiz 252
    • Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization: essential thrombocythemia (IPSET-thrombosis). Blood 2012;120:5128-5133; quiz 252.
    • (2012) Blood , vol.120 , pp. 5128-5133
    • Barbui, T.1    Finazzi, G.2    Carobbio, A.3
  • 39
    • 0346727336 scopus 로고    scopus 로고
    • Efficacy and safety of low-dose aspirin in polycythemia vera
    • Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-124.
    • (2004) N Engl J Med , vol.350 , pp. 114-124
    • Landolfi, R.1    Marchioli, R.2    Kutti, J.3
  • 40
    • 8344229870 scopus 로고    scopus 로고
    • Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
    • Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-761.
    • (2004) Am J Med , vol.117 , pp. 755-761
    • Passamonti, F.1    Rumi, E.2    Pungolino, E.3
  • 41
    • 84909595184 scopus 로고    scopus 로고
    • In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
    • Barbui T, Carobbio A, Rumi E, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 2014;124:3021-3023.
    • (2014) Blood , vol.124 , pp. 3021-3023
    • Barbui, T.1    Carobbio, A.2    Rumi, E.3
  • 42
    • 84883742082 scopus 로고    scopus 로고
    • Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study
    • Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013;27:1874-1881.
    • (2013) Leukemia , vol.27 , pp. 1874-1881
    • Tefferi, A.1    Rumi, E.2    Finazzi, G.3
  • 43
    • 84879104781 scopus 로고    scopus 로고
    • Age-related differences in disease characteristics and clinical outcomes in polycythemia vera
    • Stein BL, Saraf S, Sobol U, et al. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymph 2013;54:1989-1995.
    • (2013) Leuk Lymph , vol.54 , pp. 1989-1995
    • Stein, B.L.1    Saraf, S.2    Sobol, U.3
  • 45
    • 84897517940 scopus 로고    scopus 로고
    • JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
    • Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014;123:1544-1551.
    • (2014) Blood , vol.123 , pp. 1544-1551
    • Rumi, E.1    Pietra, D.2    Ferretti, V.3
  • 46
    • 84897568260 scopus 로고    scopus 로고
    • Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
    • Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014;123:1552-1555.
    • (2014) Blood , vol.123 , pp. 1552-1555
    • Rotunno, G.1    Mannarelli, C.2    Guglielmelli, P.3
  • 47
    • 79551491928 scopus 로고    scopus 로고
    • Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet
    • Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29:761-770.
    • (2011) J Clin Oncol , vol.29 , pp. 761-770
    • Barbui, T.1    Barosi, G.2    Birgegard, G.3
  • 48
    • 0031041044 scopus 로고    scopus 로고
    • From efficacy to safety: A polycythemia vera study group report on hydroxyurea in patients with polycythemia vera
    • Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997;34:17-23.
    • (1997) Semin Hematol , vol.34 , pp. 17-23
    • Fruchtman, S.M.1    Mack, K.2    Kaplan, M.E.3
  • 49
    • 0028913012 scopus 로고
    • Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
    • Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-1136.
    • (1995) N Engl J Med , vol.332 , pp. 1132-1136
    • Cortelazzo, S.1    Finazzi, G.2    Ruggeri, M.3
  • 50
    • 21444434751 scopus 로고    scopus 로고
    • Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
    • Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45.
    • (2005) N Engl J Med , vol.353 , pp. 33-45
    • Harrison, C.N.1    Campbell, P.J.2    Buck, G.3
  • 51
    • 28244442441 scopus 로고    scopus 로고
    • Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study
    • Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-1953.
    • (2005) Lancet , vol.366 , pp. 1945-1953
    • Campbell, P.J.1    Scott, L.M.2    Buck, G.3
  • 52
    • 84876515240 scopus 로고    scopus 로고
    • Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: The ANAHYDRET Study, a randomized controlled trial
    • Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013;121:1720-1728.
    • (2013) Blood , vol.121 , pp. 1720-1728
    • Gisslinger, H.1    Gotic, M.2    Holowiecki, J.3
  • 53
    • 0031982894 scopus 로고    scopus 로고
    • Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion
    • Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-622.
    • (1998) Blood , vol.91 , pp. 616-622
    • Sterkers, Y.1    Preudhomme, C.2    Lai, J.L.3
  • 54
    • 77950990890 scopus 로고    scopus 로고
    • An inconvenient truth
    • Spivak JL. An inconvenient truth. Blood 2010;115:2727-2728.
    • (2010) Blood , vol.115 , pp. 2727-2728
    • Spivak, J.L.1
  • 55
    • 80053945428 scopus 로고    scopus 로고
    • Treatment of polycythemia vera with hydroxyurea and pipobroman: Final results of a randomized trial initiated in 1980
    • Kiladjian JJ, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011;29:3907-3913.
    • (2011) J Clin Oncol , vol.29 , pp. 3907-3913
    • Kiladjian, J.J.1    Chevret, S.2    Dosquet, C.3
  • 56
    • 84865187605 scopus 로고    scopus 로고
    • A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: A study by the International Working Group on Myelofibrosis Research and Treatment
    • Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012;120:1197-1201.
    • (2012) Blood , vol.120 , pp. 1197-1201
    • Passamonti, F.1    Thiele, J.2    Girodon, F.3
  • 57
    • 0033781129 scopus 로고    scopus 로고
    • Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: Long-term follow-up of a randomized clinical trial
    • Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110:577-583.
    • (2000) Br J Haematol , vol.110 , pp. 577-583
    • Finazzi, G.1    Ruggeri, M.2    Rodeghiero, F.3    Barbui, T.4
  • 58
    • 54049141336 scopus 로고    scopus 로고
    • Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
    • Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112:3065-3072.
    • (2008) Blood , vol.112 , pp. 3065-3072
    • Kiladjian, J.J.1    Cassinat, B.2    Chevret, S.3
  • 59
    • 84883185991 scopus 로고    scopus 로고
    • Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a
    • Quintas-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood 2013;122:893-901.
    • (2013) Blood , vol.122 , pp. 893-901
    • Quintas-Cardama, A.1    Abdel-Wahab, O.2    Manshouri, T.3
  • 61
    • 84859856401 scopus 로고    scopus 로고
    • Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
    • Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012;119:3595-3603.
    • (2012) Blood , vol.119 , pp. 3595-3603
    • Pascale, S.1    Petrucci, G.2    Dragani, A.3
  • 62
    • 84871746842 scopus 로고    scopus 로고
    • Cardiovascular events and intensity of treatment in polycythemia vera
    • Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368:22-33.
    • (2013) N Engl J Med , vol.368 , pp. 22-33
    • Marchioli, R.1    Finazzi, G.2    Specchia, G.3
  • 63
    • 79957975519 scopus 로고    scopus 로고
    • Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients
    • Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011;117:5857-5859.
    • (2011) Blood , vol.117 , pp. 5857-5859
    • Carobbio, A.1    Thiele, J.2    Passamonti, F.3
  • 64
    • 38349175356 scopus 로고    scopus 로고
    • Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: A retrospective survey
    • Ruggeri M, Rodeghiero F, Tosetto A, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 2008;111:666-671.
    • (2008) Blood , vol.111 , pp. 666-671
    • Ruggeri, M.1    Rodeghiero, F.2    Tosetto, A.3
  • 65
    • 34047236618 scopus 로고    scopus 로고
    • Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia
    • Teofili L, Giona F, Martini M, et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol 2007;25:1048-1053.
    • (2007) J Clin Oncol , vol.25 , pp. 1048-1053
    • Teofili, L.1    Giona, F.2    Martini, M.3
  • 66
    • 84858126395 scopus 로고    scopus 로고
    • Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: Clinical and biologic features, treatment, and long-term outcome
    • Giona F, Teofili L, Moleti ML, et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood 2012;119:2219-2227.
    • (2012) Blood , vol.119 , pp. 2219-2227
    • Giona, F.1    Teofili, L.2    Moleti, M.L.3
  • 67
    • 84901714382 scopus 로고    scopus 로고
    • Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
    • Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014;123:e123-133.
    • (2014) Blood , vol.123 , pp. e123-e133
    • Rampal, R.1    Al-Shahrour, F.2    Abdel-Wahab, O.3
  • 68
    • 84863393110 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
    • Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807.
    • (2012) N Engl J Med , vol.366 , pp. 799-807
    • Verstovsek, S.1    Mesa, R.A.2    Gotlib, J.3
  • 69
    • 84857837774 scopus 로고    scopus 로고
    • JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
    • Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-798.
    • (2012) N Engl J Med , vol.366 , pp. 787-798
    • Harrison, C.1    Kiladjian, J.J.2    Al-Ali, H.K.3
  • 70
    • 84891303523 scopus 로고    scopus 로고
    • Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
    • Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047-4053.
    • (2013) Blood , vol.122 , pp. 4047-4053
    • Cervantes, F.1    Vannucchi, A.M.2    Kiladjian, J.J.3
  • 71
    • 84887014885 scopus 로고    scopus 로고
    • Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: Results of a median 2-year follow-up of COMFORT-I
    • Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013;98:1865-1871.
    • (2013) Haematologica , vol.98 , pp. 1865-1871
    • Verstovsek, S.1    Mesa, R.A.2    Gotlib, J.3
  • 72
  • 73
    • 84865192181 scopus 로고    scopus 로고
    • Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: Survival advantage in comparison to matched historical controls
    • Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012;120:1202-1209.
    • (2012) Blood , vol.120 , pp. 1202-1209
    • Verstovsek, S.1    Kantarjian, H.M.2    Estrov, Z.3
  • 74
    • 84897528714 scopus 로고    scopus 로고
    • Impact of ruxolitinib on the natural history of primary myelofibrosis: A comparison of the DIPSS and the COMFORT-2 cohorts
    • Passamonti F, Maffioli M, Cervantes F, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 2014;123:1833-1835.
    • (2014) Blood , vol.123 , pp. 1833-1835
    • Passamonti, F.1    Maffioli, M.2    Cervantes, F.3
  • 75
    • 85039882889 scopus 로고    scopus 로고
    • Pacritinib, a dual JAK2/FLT3 inhibitor: An integrated efficacy and safety analysis of phase II trial data in patients with primary and secondary myelofibrosis (MF) and platelet counts ≤100,000/μl
    • Presented at the
    • Dean JP, Cernohous P, Komrokji RS, et al. Pacritinib, a dual JAK2/FLT3 inhibitor: an integrated efficacy and safety analysis of phase II trial data in patients with primary and secondary myelofibrosis (MF) and platelet counts ≤100,000/μl. Presented at the 55th ASH Annual Meeting and Exposition; December 7-20, 2013; New Orleans, Louisiana. Abstract 395.
    • 55th ASH Annual Meeting and Exposition; December 7-20, 2013; New Orleans, Louisiana
    • Dean, J.P.1    Cernohous, P.2    Komrokji, R.S.3
  • 76
    • 84878951826 scopus 로고    scopus 로고
    • Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
    • Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013;27:1322-1327.
    • (2013) Leukemia , vol.27 , pp. 1322-1327
    • Pardanani, A.1    Laborde, R.R.2    Lasho, T.L.3
  • 77
    • 84856866188 scopus 로고    scopus 로고
    • Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
    • Alvarez-Larran A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 2012;119:1363-1369.
    • (2012) Blood , vol.119 , pp. 1363-1369
    • Alvarez-Larran, A.1    Pereira, A.2    Cervantes, F.3
  • 78
    • 84893733177 scopus 로고    scopus 로고
    • A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
    • Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 2014;120:513-520.
    • (2014) Cancer , vol.120 , pp. 513-520
    • Verstovsek, S.1    Passamonti, F.2    Rambaldi, A.3
  • 79
    • 84921891315 scopus 로고    scopus 로고
    • Ruxolitinib versus standard therapy for the treatment of polycythemia vera
    • Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015;372:426-435.
    • (2015) N Engl J Med , vol.372 , pp. 426-435
    • Vannucchi, A.M.1    Kiladjian, J.J.2    Griesshammer, M.3
  • 80
    • 84887193830 scopus 로고    scopus 로고
    • The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
    • Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 2013;122:1192-1202.
    • (2013) Blood , vol.122 , pp. 1192-1202
    • Heine, A.1    Held, S.A.2    Daecke, S.N.3
  • 81
    • 84880323178 scopus 로고    scopus 로고
    • Progressive multifocal leukoencephalopathy associated with ruxolitinib
    • Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 2013;369:197-198.
    • (2013) N Engl J Med , vol.369 , pp. 197-198
    • Wathes, R.1    Moule, S.2    Milojkovic, D.3
  • 82
    • 84881416684 scopus 로고    scopus 로고
    • Bilateral toxoplasmosis retinitis associated with ruxolitinib
    • Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med 2013;369:681-683.
    • (2013) N Engl J Med , vol.369 , pp. 681-683
    • Goldberg, R.A.1    Reichel, E.2    Oshry, L.J.3
  • 83
    • 84905679218 scopus 로고    scopus 로고
    • Disseminated tuberculosis associated with ruxolitinib
    • Hopman RK, Lawrence SJ, Oh ST. Disseminated tuberculosis associated with ruxolitinib. Leukemia 2014;28:1750-1751.
    • (2014) Leukemia , vol.28 , pp. 1750-1751
    • Hopman, R.K.1    Lawrence, S.J.2    Oh, S.T.3
  • 84
    • 84870836370 scopus 로고    scopus 로고
    • Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: A case report
    • Colomba C, Rubino R, Siracusa L, et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes 2012;5:552.
    • (2012) BMC Res Notes , vol.5 , pp. 552
    • Colomba, C.1    Rubino, R.2    Siracusa, L.3
  • 85
    • 84877618100 scopus 로고    scopus 로고
    • An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor
    • Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest 2013;143:1478-1479.
    • (2013) Chest , vol.143 , pp. 1478-1479
    • Wysham, N.G.1    Sullivan, D.R.2    Allada, G.3
  • 86
    • 34248364065 scopus 로고    scopus 로고
    • Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essentialthrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)
    • Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essentialthrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007;31:737-740.
    • (2007) Leuk Res , vol.31 , pp. 737-740
    • Mesa, R.A.1    Verstovsek, S.2    Cervantes, F.3
  • 87
    • 33751507891 scopus 로고    scopus 로고
    • Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: A distinct aspirin-responsive and coumadin-resistant arterial thrombophilia
    • Michiels JJ, Berneman Z, Schroyens W, et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets 2006;17:528-544.
    • (2006) Platelets , vol.17 , pp. 528-544
    • Michiels, J.J.1    Berneman, Z.2    Schroyens, W.3
  • 88
    • 84886769456 scopus 로고    scopus 로고
    • Struggling with myelofibrosis-associated anemia
    • Guglielmelli P, Vannucchi AM. Struggling with myelofibrosis-associated anemia. Leuk Res 2013;37:1429-1431.
    • (2013) Leuk Res , vol.37 , pp. 1429-1431
    • Guglielmelli, P.1    Vannucchi, A.M.2
  • 89
    • 84902602920 scopus 로고    scopus 로고
    • Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis
    • Elli EM, Belotti A, Aroldi A, et al. Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis. Mediterr J Hematol Infect Dis 2014;6:e2014042.
    • (2014) Mediterr J Hematol Infect Dis , vol.6 , pp. e2014042
    • Elli, E.M.1    Belotti, A.2    Aroldi, A.3
  • 90
    • 80053572889 scopus 로고    scopus 로고
    • Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents
    • Ghanima W, Junker P, Hasselbalch HC, et al. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J Haematol 2011;155:248-255.
    • (2011) Br J Haematol , vol.155 , pp. 248-255
    • Ghanima, W.1    Junker, P.2    Hasselbalch, H.C.3
  • 91
    • 33745811661 scopus 로고    scopus 로고
    • Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic
    • Mesa RA, Nagorney DS, Schwager S, et al. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006;107:361-370.
    • (2006) Cancer , vol.107 , pp. 361-370
    • Mesa, R.A.1    Nagorney, D.S.2    Schwager, S.3
  • 92
    • 0141705389 scopus 로고    scopus 로고
    • Nonhepatosplenic extramedullary hematopoiesis: Associated diseases, pathology, clinical course, and treatment
    • Koch CA, Li CY, Mesa RA, Tefferi A. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc 2003;78:1223-1233.
    • (2003) Mayo Clin Proc , vol.78 , pp. 1223-1233
    • Koch, C.A.1    Li, C.Y.2    Mesa, R.A.3    Tefferi, A.4
  • 94
    • 77956302639 scopus 로고    scopus 로고
    • Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis
    • Alchalby H, Badbaran A, Zabelina T, et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010;116:3572-3581.
    • (2010) Blood , vol.116 , pp. 3572-3581
    • Alchalby, H.1    Badbaran, A.2    Zabelina, T.3
  • 95
    • 84890911661 scopus 로고    scopus 로고
    • Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: A cohort analysis from the center for international blood and marrow transplant research
    • Gupta V, Malone AK, Hari PN, et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2014;20:89-97.
    • (2014) Biol Blood Marrow Transplant , vol.20 , pp. 89-97
    • Gupta, V.1    Malone, A.K.2    Hari, P.N.3
  • 96
    • 84905986086 scopus 로고    scopus 로고
    • MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
    • Rondelli D, Goldberg JD, Isola L, et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood 2014;124:1183-1191.
    • (2014) Blood , vol.124 , pp. 1183-1191
    • Rondelli, D.1    Goldberg, J.D.2    Isola, L.3
  • 97
    • 84865174824 scopus 로고    scopus 로고
    • Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors
    • Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood 2012;120:1367-1379.
    • (2012) Blood , vol.120 , pp. 1367-1379
    • Gupta, V.1    Hari, P.2    Hoffman, R.3
  • 98
    • 84902581112 scopus 로고    scopus 로고
    • Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
    • Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 2014;123:3832-3842.
    • (2014) Blood , vol.123 , pp. 3832-3842
    • Spoerl, S.1    Mathew, N.R.2    Bscheider, M.3
  • 99
    • 84865735256 scopus 로고    scopus 로고
    • Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
    • Koppikar P, Bhagwat N, Kilpivaara O, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012;489:155-159.
    • (2012) Nature , vol.489 , pp. 155-159
    • Koppikar, P.1    Bhagwat, N.2    Kilpivaara, O.3
  • 100
    • 79959232873 scopus 로고    scopus 로고
    • Recombinant interferon-alpha may retard progression of early primary myelofibrosis: A preliminary report
    • Silver RT, Vandris K, Goldman JJ. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood 2011;117:6669-6672.
    • (2011) Blood , vol.117 , pp. 6669-6672
    • Silver, R.T.1    Vandris, K.2    Goldman, J.J.3
  • 101
    • 85039883958 scopus 로고    scopus 로고
    • Interim analysis of a phase II pilot trial of ruxolitinib combined with danazol for patients with primary myelofibrosis (MF), post essential thrombocythemia-myelofibrosis (post ET), and post polycythemia vera myelofibrosis (PV MF) suffering from anemia
    • Presented at the
    • Gowin KL, Dueck AC, Mascarenhas JO, et al. Interim analysis of a phase II pilot trial of ruxolitinib combined with danazol for patients with primary myelofibrosis (MF), post essential thrombocythemia-myelofibrosis (post ET), and post polycythemia vera myelofibrosis (PV MF) suffering from anemia. Presented at the 56th ASH Annual Meeting and Exposition; December 6-9, 2014; San Francisco, California. Abstract 3206.
    • 56th ASH Annual Meeting and Exposition; December 6-9, 2014; San Francisco, California
    • Gowin, K.L.1    Dueck, A.C.2    Mascarenhas, J.O.3
  • 102
    • 85039878521 scopus 로고    scopus 로고
    • A multicenter phase-Ib/II study of ruxolitinib/pomalidomide combination therapy in patients with primary and secondary myelofibrosis: Safety data from the Mpnsg-0212 trial (NCT01644110)
    • Presented at the
    • Stegelmann F, Griesshammer M, Reiter A, et al. A multicenter phase-Ib/II study of ruxolitinib/pomalidomide combination therapy in patients with primary and secondary myelofibrosis: safety data from the Mpnsg-0212 trial (NCT01644110). Presented at the 56th ASH Annual Meeting and Exposition; December 6-9, 2014; San Francisco, California. Abstract 3161.
    • 56th ASH Annual Meeting and Exposition; December 6-9, 2014; San Francisco, California
    • Stegelmann, F.1    Griesshammer, M.2    Reiter, A.3
  • 104
  • 105
    • 85039877214 scopus 로고    scopus 로고
    • HARMONY: An open-label, multicenter, 2-arm, dose-finding, phase 1b study of the combination of ruxolitinib and buparlisib (BKM120) in patients with myelofibrosis (MF)
    • Presented at the
    • Durrant S, Koren-Michowitz M, Lavie D, et al. HARMONY: an open-label, multicenter, 2-arm, dose-finding, phase 1b study of the combination of ruxolitinib and buparlisib (BKM120) in patients with myelofibrosis (MF). Presented at the 56th ASH Annual Meeting and Exposition; December 6-9, 2014; San Francisco, California. Abstract 710.
    • 56th ASH Annual Meeting and Exposition; December 6-9, 2014; San Francisco, California
    • Durrant, S.1    Koren-Michowitz, M.2    Lavie, D.3
  • 107
    • 85027918531 scopus 로고    scopus 로고
    • Novel myelofibrosis treatment strategies: Potential partners for combination therapies
    • Stein BL, Swords R, Hochhaus A, Giles F. Novel myelofibrosis treatment strategies: potential partners for combination therapies. Leukemia 2014;28:2139-2147.
    • (2014) Leukemia , vol.28 , pp. 2139-2147
    • Stein, B.L.1    Swords, R.2    Hochhaus, A.3    Giles, F.4
  • 108
    • 84928020717 scopus 로고    scopus 로고
    • Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results
    • abstract
    • Verstovsek S, Mesa RA, Foltz LM, et al. Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: stage 1 results [abstract]. J Clin Oncol 2014;32(Suppl):Abstract 7114.
    • (2014) J Clin Oncol , vol.32
    • Verstovsek, S.1    Mesa, R.A.2    Foltz, L.M.3
  • 110
    • 0029767865 scopus 로고    scopus 로고
    • Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system
    • Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996;88:1013-1018.
    • (1996) Blood , vol.88 , pp. 1013-1018
    • Dupriez, B.1    Morel, P.2    Demory, J.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.